Gapping up
In reaction to earnings/guidance:
- ZG +12.7%, HUBS +8.7%, GDDY +7.7% (also announces $3 bln share repurchase plan), MNTV +7.6%, BLDE +6.7%, FLO +5.9%, BE +5.9%, COOP +5.4%, MPWR +4.8% (also announces a 25% increase in dividend), PRLB +4.7%, YELP +4.5%, EXPE +4.3%, NET +4.1% (also acquires Vectrix), OFC +3.7%, G +3%, COHU +2.6%, ZEN +2.5% (also rejects unsolicited acquisition proposal from private equity firms), RARE +2.3%, FRT +2%, LADR +1.8%, FE +1.4%, MTD +1.2%, MHK +0.9%, BIO +0.8%
Other news:
- DZSI +8.8% (files for $150 mln offering; also files for offering by selling shareholder)
- XPEL +8.8% (to be added to S&P SmallCap 600)
- SAVA +6.4% (FDA denies Citizen Petition filed on behalf of short sellers)
- ABCL +5.4% (AbCellera Biologics and Eli Lilly (LLY) to supply up to 600K doses of Bebtelovimab to the US Government)
- OPEN +4.1% (in sympathy with strong ZG earnings)
- NGL +3.6% (signs new long-term produced water transportation recycling and disposal agreement)
- RDFN +3.1% (in sympathy with strong ZG earnings)
- NVAX +3% (NVX-CoV2373 achieved primary effectiveness endpoint in pediatric trial)
- OSUR +2.4% (files for $300 mln mixed securities shelf offering)
- OBSV +2.1% (enters into licensing agreement with Theramex for the commercialization of linzagolix)
Analyst comments:
- RARE +2.3% (upgraded to Overweight from Neutral at JP Morgan)
- CRS +1.7% (upgraded to Overweight from Neutral at JP Morgan)
- BG +0.9% (upgraded to Buy from Neutral at BofA Securities)